Sipuleucel-T (trade name Provenge) has been approved since September 2014 for men with metastatic prostate cancer who have few or no symptoms and do not yet require chemotherapy. In the dossier assessment conducted by the German Institute for Quality and Efficiency in Health Care (IQWiG) in January 2015, no added benefit could be derived for sipuleucel-T.

In an addendum, the Institute now examined information subsequently submitted by the manufacturer in the commenting procedure: According to the findings, there is an indication of added benefit; however, the extent is non-quantifiable.

For more details, go to: https://www.iqwig.de/en/press/press-releases/press-releases/sipuleucel-t-in-prostate-cancer-indication-of-added-benefit.6618.html